Loading stock data…
TLX
$11.26+0.26 (+2.36%)
Market ClosedLast close May 1
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Telix Pharmaceuticals Limited in the Healthcare sector is trading at $11.26. The stock is currently 40% below its 52-week high of $18.87, remaining 17.5% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why TLX maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.26
Potential Upside
5%
Whystock Fair Value$11.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therape...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.84%
Volume
Today's trading volume
129,475
Recent News
Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares
Those following along with Telix Pharmaceuticals Limited ( ASX:TLX ) will no doubt be intrigued by the recent purchase...
How TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) Investors
Earlier this week, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA trial dosimetry results for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in key non-target organs and supporting further evaluation in earlier-stage disease. The data suggest TLX597-Tx may allow higher treatment doses while limiting toxicity, potentially expanding access to lutetium-based therapy across more prostate cancer patients and geographies. We’ll now explore how these...
Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End
Telix Pharmaceuticals (NASDAQ:TLX) hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical investigator emphasizing the need for more patient-centric dosing and improved tolerability as PSMA-ta
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock.
Regeneron will face competition from new market entrants later this year, but upbeat data could change everything.
Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing?
Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best Australian stocks to buy in 2026. Telix Pharmaceuticals Limited (NASDAQ:TLX) is using a combination of internal programs and partnership arrangements to expand its product portfolio. On April 21, the company announced that it plans to present clinical trial data for its prostate cancer drug candidate at the […]